Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
INSM

INSM - Insmed Inc Stock Price, Fair Value and News

$74.63+0.72 (+0.97%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

INSM RSI Chart

2024AprJul20406080100

INSM Valuation

Market Cap

12.8B

Price/Earnings (Trailing)

-15.98

Price/Sales (Trailing)

39.03

EV/EBITDA

-17.63

Price/Free Cashflow

-21.72

INSM Price/Sales (Trailing)

20222023202410203040

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

INSM Fundamentals

INSM Revenue

Revenue (TTM)

328.6M

Rev. Growth (Yr)

16.98%

Rev. Growth (Qtr)

19.66%

20102012201420162018202020222024050M100M150M200M250M300M350M

INSM Earnings

Earnings (TTM)

-802.7M

Earnings Growth (Yr)

-22.79%

Earnings Growth (Qtr)

-91.36%

20102012201420162018202020222024-800M-600M-400M-200M0200M

INSM Price Action

Last 7 days

5.1%

Last 30 days

-0.3%

Last 90 days

16.8%

Trailing 12 Months

179.8%

INSM Profitability

EBT Margin

-243.37%

Return on Equity

-2.1K%

Return on Assets

-44.34%

Free Cashflow Yield

-4.61%

INSM Financial Health

Current Ratio

2.71

Debt/Equity

24.39

Debt/Cashflow

-0.61

INSM Investor Care

Shares Dilution (1Y)

19.51%

Diluted EPS (TTM)

-5.39

INSM Alerts

  • 3 major insider sales recently.
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
20102012201420162018202020222024050M100M150M200M250M300M350M
Net sales
YearQ1Q2Q3Q4
2024315.5M328.6M00
2023257.5M269.5M280.8M305.2M
2022201.4M221.2M242.2M245.4M
2021167.8M170.6M173.8M188.5M
2020151.4M163.9M168.7M164.4M
201937.2M64.5M100.6M136.5M
20183.5M6.1M8.5M17.3M
2017588.0K593.0K781.0K1.6M
2016408.0K504.0K567.0K604.0K
20154.0M2.1M178.0K261.0K
20149.6M7.7M5.8M0
20135.3M7.4M9.4M11.5M
20123.2M000
20116.6M5.7M4.3M4.4M
201009.2M8.1M6.9M
200900010.4M
INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
 CEO
 WEBSITEinsmed.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES736

Insmed Inc Frequently Asked Questions


What is the ticker symbol for Insmed Inc? What does INSM stand for in stocks?

INSM is the stock ticker symbol of Insmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Insmed Inc (INSM)?

As of Fri Sep 13 2024, market cap of Insmed Inc is 12.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers.

Is Insmed Inc a good stock to buy?

The fair value guage provides a quick view whether INSM is over valued or under valued. Whether Insmed Inc is cheap or expensive depends on the assumptions which impact Insmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSM.

What is Insmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 13 2024, INSM's PE ratio (Price to Earnings) is -15.98 and Price to Sales (PS) ratio is 39.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Insmed Inc's stock?

In the past 10 years, Insmed Inc has provided 0.189 (multiply by 100 for percentage) rate of return.